Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Medtronic
Dow
Moodys
McKesson
Colorcon

Last Updated: January 27, 2023

CLINICAL TRIALS PROFILE FOR FARXIGA


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Farxiga

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02235298 ↗ Dapagliflozin Effects on Epicardial Fat Completed AstraZeneca Phase 4 2015-09-01 The purpose of this research study is to learn about the effect of Dapagliflozin (Farxiga) on the fat of the heart.
NCT02235298 ↗ Dapagliflozin Effects on Epicardial Fat Completed University of Miami Phase 4 2015-09-01 The purpose of this research study is to learn about the effect of Dapagliflozin (Farxiga) on the fat of the heart.
NCT02371187 ↗ Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training? Completed AstraZeneca Phase 2 2015-06-01 Exercise is frequently prescribed as a favorable lifestyle intervention to prevent/reverse type 2 diabetes. It is also prescribed in addition to concurrent pharmacological treatment, such as metformin. Recent data (animal and human) suggest that metformin may attenuate the favorable benefits of exercise training. In light of the physiological mechanism of Dapagliflozin (sodium-glucose co-transporter 2 (SGLT2) inhibition), one might speculate that rather than inhibit, it will augment the favorable adaptations to exercise training.
NCT02371187 ↗ Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training? Completed Christopher Bell Phase 2 2015-06-01 Exercise is frequently prescribed as a favorable lifestyle intervention to prevent/reverse type 2 diabetes. It is also prescribed in addition to concurrent pharmacological treatment, such as metformin. Recent data (animal and human) suggest that metformin may attenuate the favorable benefits of exercise training. In light of the physiological mechanism of Dapagliflozin (sodium-glucose co-transporter 2 (SGLT2) inhibition), one might speculate that rather than inhibit, it will augment the favorable adaptations to exercise training.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Farxiga

Condition Name

Condition Name for Farxiga
Intervention Trials
Diabetes Mellitus, Type 2 12
Type 2 Diabetes 2
Diabetes 2
Type 2 Diabetes Mellitus 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Farxiga
Intervention Trials
Diabetes Mellitus 22
Diabetes Mellitus, Type 2 21
Diabetes Mellitus, Type 1 5
Heart Failure 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Farxiga

Trials by Country

Trials by Country for Farxiga
Location Trials
United States 108
Brazil 16
India 7
Canada 3
Argentina 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Farxiga
Location Trials
Texas 16
New York 10
California 8
Florida 6
Missouri 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Farxiga

Clinical Trial Phase

Clinical Trial Phase for Farxiga
Clinical Trial Phase Trials
Phase 4 23
Phase 3 6
Phase 2 8
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Farxiga
Clinical Trial Phase Trials
Completed 17
Recruiting 12
Unknown status 6
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Farxiga

Sponsor Name

Sponsor Name for Farxiga
Sponsor Trials
AstraZeneca 15
The University of Texas Health Science Center at San Antonio 10
University at Buffalo 4
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Farxiga
Sponsor Trials
Other 64
Industry 20
NIH 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Baxter
McKesson
AstraZeneca
Express Scripts
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.